ATRO Medical and the EIC Accelerator: Meniscus Still in Trials

ATRO Medical, based in Nijmegen, makes Artimis, a polymer prosthesis to replace the meniscus in patients who have chronic knee pain after it was removed. Its EIC project counted 350,000 relatively young patients missing the lateral meniscus, the one on the outside of the knee, with 70,000 new cases a year and no clinical solution. The implant is meant to postpone a total knee replacement.

The European Innovation Council granted €2,499,403 towards AL U KNEED, a €3.6 million project from April 2023 to March 2026, to "finalize pre-clinical activities, conduct a FIH-study, and obtain CE-marking" by 2026. The first lateral patient was treated in October 2024 at Radboud University Medical Center, according to ATRO. In February 2026, a month before the project ended, the company raised €3 million to prepare pivotal trials in the US and Europe. No CE Mark has been announced.

Where ATRO Medical Stands Now

The February 2026 round came from 819 Capital, Thuja Capital, Bolwork International Investment, DSM-Firmenich Ventures and Samaplast, and was used to expand clinical evidence, prepare pivotal trials and improve manufacturing and regulatory readiness. Chairman Michiel Schwartz said: "We have cracked the code for patients with post-meniscectomy pain." In June 2026 the FDA granted the lateral implant Breakthrough Device designation, which the medial version already had. The company has published no clinical results.

The Technology: A Polymer Meniscus

ATRO first tested a medial implant, for the inner side of the knee. Its first AIR study, registered on ClinicalTrials.gov, enrolled 5 patients from 2018 and was terminated as "halted prematurely" in 2021; a follow-up study, AIR2, planned 10. The EIC project applied the approach to the lateral side: the report lists "3x1 million dynamic endurance tests", mechanical and pull-out testing and production of five prosthesis sizes before the lateral EARTH study.

What the EIC Project Promised, and What CORDIS Shows

The only published report covers April 2023 to June 2024, when the first-in-human documents were with the ethics committee and approval was expected "in the coming weeks". It targeted market entry in 2026 after CE marking, and commissioned a health economics model for later publication. The final period of the project has no public report, and the CE marking it promised has not been announced.

1. Pre-clinical workDeliveredEndurance and pull-out tests.
2. First-in-human studyStartedFirst patient October 2024.
3. CE marking by 2026Not announcedPivotal trials pending.
4. Health economics modelNot publishedCommissioned in 2024.

The Money

ATRO does not publish accounts or its total funding. Its site lists earlier support from EUROSTARS and the Dutch Arthritis Society. Without a CE Mark it has no product it can sell.

What Cannot Be Checked

Why Europe Should Care

The EIC funded a Dutch device aimed at a group of patients with, by its own account, no treatment option. The work is going ahead with new investors, but on a longer path than the one the EIC paid for: pivotal trials first, CE marking later.

The Verdict

ATRO Medical and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.